Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Valerie Chamberlain Santos"'
Autor:
Mark Uhlik, Daniel Pointing, Seema Iyer, Luka Ausec, Miha Štajdohar, Robert Cvitkovič, Matjaž Žganec, Kerry Culm, Valerie Chamberlain Santos, Bronislaw Pytowski, Mokenge Malafa, Hong Liu, Arthur M. Krieg, Jeeyun Lee, Rafael Rosengarten, Laura Benjamin
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionMost predictive biomarkers approved for clinical use measure single analytes such as genetic alteration or protein overexpression. We developed and validated a novel biomarker with the aim of achieving broad clinical utility. The Xerna™
Externí odkaz:
https://doaj.org/article/3cea1d0d51c242f6bda7d52c9e0ee0df
Autor:
Amelia B. Zelnak, Heinz-Josef Lenz, Kerry Culm, Lukas Makris, Valerie Chamberlain Santos, Hagop Youssoufian, Colleen Mockbee, Kathy D. Miller
Publikováno v:
Cancer Research. 83:OT2-16
Objective: The objective of this Phase 2, open-label, multicenter study is to investigate the antitumor activity of navicixizumab monotherapy or in combination with chemotherapy in patients with advanced solid tumors. Cohort C will enroll triple-nega
Autor:
Paul Eliezer Oberstein, Meredith Pelster, Kerry Culm, Valerie Chamberlain Santos, Andrew Koustenis, Colleen M. Mockbee, Hagop Youssoufian, John C. Krauss
Publikováno v:
Journal of Clinical Oncology. 41:TPS263-TPS263
TPS263 Background: The objective of this Phase 2, open-label, multicenter study is to investigate the antitumor activity of navicixizumab monotherapy or in combination with chemotherapy in patients with advanced solid tumors (NCT05453825). Cohort A w
Autor:
Seema Iyer, Luka Ausec, Daniel Pointing, Matjaz Zganec, Robert Cvitkovic, Miha Stajdohar, Valerie Chamberlain Santos, Kerry Culm, Mokenge Malafa, Jeeyun Lee, Rafael Rosengarten, Laura Benjamin, Mark T. Uhlik
Publikováno v:
Cancer Research. 82:1232-1232
While numerous anti-angiogenic and immune targeting therapies have become standard-of-care treatments for oncology, predictive biomarkers for these agents have been either entirely lacking or challenged by inconsistencies across indications. We have
Autor:
Thomas A. Keating, Ravi V. J. Chari, Luke Harris, Thomas Chittenden, Valerie Chamberlain Santos, Prerak Shah, Cristina Gavrilescu, Richard Gregory, Cynthia J. Guidi, Kerry Donahue, Katharine C. Lai, Rui Wu, Yimao Liu
Publikováno v:
Cancer Research. 78:2900-2900
Purpose: Solid tumor growth and metastasis requires continuous formation of new blood vessels. Endoglin/CD105 is a well-acknowledged endothelial cell proliferation marker, which is strongly expressed in tumor-associated vasculature. Vasculature targe